Lisa Cook sues Trump over firing attempt, emergency hearing set
H.C. Wainwright reiterated its buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ:BEAM) on Friday, June 13. Currently trading at $17.06, the stock has significant upside potential according to analyst consensus, with targets ranging from $20 to $80. InvestingPro analysis indicates the stock is currently fairly valued, with a market capitalization of $1.66 billion. The firm cited updated data from the Phase 1/2 BEACON trial evaluating BEAM-101, a base-edited cell therapy for sickle cell disease patients with severe vaso-occlusive crises. With a beta of 2.08, BEAM shows higher volatility than the broader market, reflecting the typical risk profile of clinical-stage biotech companies. InvestingPro subscribers can access detailed risk metrics and 12+ exclusive ProTips for deeper analysis.
The data presented at the European Hematology Association Congress in Milan showed robust increases in fetal hemoglobin above 60% and reductions in sickle hemoglobin below 40%. This 60/40 trait is considered a benchmark for therapeutic success by physicians and regulators in the treatment of sickle cell disease.
Beam Therapeutics reported no vaso-occlusive crises in patients post-engraftment and no new serious adverse events attributed to BEAM-101. H.C. Wainwright described these updated results as "encouraging" and stated they reveal "an emerging differentiated profile for BEAM-101."
The company announced that enrollment in the BEACON trial is complete with 30 patients, and 26 patients had been dosed as of June 13. Beam remains on track to complete dosing by mid-2025, with the next data update expected by the end of 2025.
Beam Therapeutics hosted a webcast on Friday, June 13, to discuss these findings and other data presented at the European Hematology Association Congress. The company maintains a strong financial position with a current ratio of 8.81, though it reported an EBITDA of -$408.7M in the last twelve months. For comprehensive analysis of BEAM’s financial health and growth prospects, check out the detailed Pro Research Report available on InvestingPro, part of our coverage of 1,400+ US stocks.
In other recent news, Beam Therapeutics reported positive data from its BEACON Phase 1/2 clinical trial of BEAM-101, a treatment for sickle cell disease. The trial showed consistent results, with all treated patients achieving significant hemoglobin improvements and no vaso-occlusive crises reported post-treatment. Additionally, Beam Therapeutics announced that BEAM-101 received orphan drug designation from the FDA, providing benefits like tax credits and potential market exclusivity. Beam Therapeutics also received orphan drug status for BEAM-302, its treatment for alpha-1 antitrypsin deficiency (AATD), further supported by the FDA’s RMAT designation, which could accelerate its development. Early clinical trials for BEAM-302 have shown promise, with significant correction of the PiZ mutation in AATD patients. H.C. Wainwright maintained its Buy rating on Beam Therapeutics, with a price target of $80, following the presentation of promising trial results for BEAM-302. The company plans to release additional data and begin dosing in new trial cohorts later this year. These developments highlight Beam Therapeutics’ ongoing progress in advancing its genetic therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.